Association of HLA-DRB1 alleles with giant cell tumour of bone

S S Varanasi, N A Athanasou, I Briceno, S S Papiha, H K Datta

Abstract

Aim—To examine the possible influence of the MHC class II antigens alleles in the formation of the multinucleate aggressive giant cell tumour of bone.

Methods—HLA class II antigen alleles were investigated in eight white patients from north east England with confirmed diagnosis of giant cell tumour of bone. All had locally aggressive, immunophenotypically HLA-DR negative giant cell tumours.

Results—Five of the eight patients were found to be positive for HLA-DRB1*0801/3, the distribution of this allele in healthy white controls being quite low (2%). All but one of the patients possessing DRB1*080 also expressed DRB1*070.

Conclusions—HLA-DRB1*080 is predominant in patients with immunophenotypic HLA-DR negative giant cell tumour of bone; individuals with the genotype 070/080 are at particularly high risk of developing giant cell tumour of bone.

(J Clin Pathol 1999;52:782-784)

Keywords: HLA-DR genotyping; giant cell tumour of bone; osteoclastogenesis

Giant cell tumour of bone, constituting 5% of all bone tumours, commonly occurs in the third and fourth decade of life.¹ It is a potentially aggressive stromal growth capable of causing considerable damage owing to its bone resorbing capacity. Although occasionally known to metastasise, most tend to produce damage at the primary site. The aetiology of these tumours is unknown and there is no evidence of familial occurrence.

In recent years characterisation studies have attempted to classify giant cells into two main subtypes on the basis of their resorptive activity, calcitonin responsiveness, and HLA-DR immunophenotypic status.² It has been suggested that giant cells showing avid bone resorptive activity tend to be HLA-DR negative and are sensitive to inhibition by calcitonin, while cells that are HLA-DR positive lack resorptive activity and are insensitive to calcitonin.² However, exceptions to this association have been reported, with immunophenotypic HLA-DR positivity and responsiveness to calcitonin.³ This apparent association between the HLA-DR and giant cell tumour of bone led us to examine the possible influence of the MHC class II antigen alleles in the formation of aggressive multinucleate giant cell tumours.

Methods

SELECTION OF PATIENTS

We selected eight white British patients from north east England with a confirmed diagnosis of locally destructive giant cell tumour of bone. The samples consisted of biopsies collected for pathological examination from patients undergoing surgery for resection of the tumour. The tumours selected did not express HLA-DR antigen and showed evidence of extensive bone resorption.

HLA-DR GENOTYPING

Embedded tissue was scraped free from the paraffin blocks and washed in xylol. The remnant bone and soft tissue were suspended in two volumes of ethanol, agitated, and collected by centrifugation. Liquid nitrogen was added to the tissue and the supercooled bone was crushed into smaller pieces. The crushed bone was incubated at 37°C for three days in ESP solution (0.5 mM ethylene diamine tetra-acetic acid (pH 9), 0.019 mg/ml sodium dodecyl sulphate (SDS), 1 mg/ml proteinase K). Genomic DNA was extracted by

Figure 1 A representative Southern blot of HLA-DRB1 allele genotyping carried out using sequence specific oligonucleotide (SSO) analysis. The details of the PCR conditions employed for the amplification of the genomic DNA, including the sequences of the primers used, are given in the text. Following agarose gel electrophoresis, the amplified DNA was transferred to nylon filter by Southern transfer and sequentially probed with oligonucleotide probes (table 1). The genotyping was carried out as recommended by The International Histocompatibility Workshop and Conference.

Department of Clinical Biochemistry, The Medical School, University of Newcastle upon Tyne NE2 4HH, UK
S S Varanasi
H K Datta

Department of Pathology, Nuffield Orthopaedic Centre, Headington, Oxford OX3 7LD, UK
N A Athanasou

Department of Human Genetics, The Medical School, University of Newcastle, Newcastle upon Tyne NE2 4HH, UK
I Briceno
S S Papiha

Correspondence to: Dr Datta.
email: h.k.datta@ncl.ac.uk

Accepted for publication 1 June 1999

Table 1 The sequence of sense and antisense of DRB1 oligonucleotide probes

DRB1	Sequence	Amino acid position 5'	
1. 0102, 1201, DRB5*0201, 0202	CTACGGGGCTGTGGAGA	82	Sense
2. 0401-09	ACTTCTATCACCAAGAG	30	Sense
3. 0405, 0409, 0801 (0803, 1303)	GCGGCCTAGCGCCGAGT	54	Sense
4. 1201	AGGAGGAGCTCCTGCGC	34	Sense
5. 0701, 0702	ACGGAGCTAGGGCGGCC	51	Sense
6. 0901	TGCGGTATCTGCACAGA	24	Sense
7. 0801, 0802, 0803	GCGGGCCCTGGTGGACA	71	Sense
8. 1001	GAGCGGAGGCGTGCCGC	69	Sense
9. DRB1 1401	CTGCGGAGCACTGGAAC	57	Sense
10. 0101, 0102, 0103	ATAGATGCATCTTTCCA	32	Antisense
11. 0102, 1201, 1401	TGTCTGCAATAGGTGTC	81	Antisense
12. 1501, 1502, DRB5*0201, 0202	CGGCCCGCGCTGCTCC	74	Antisense
13. 0301, 0302	TGCAGTAGTTGTCCACC	80	Antisense
14. 0401, 0409	CACCGCGGCCGCTTCTGCTC	75	Antisense
15. 0103, 0402, 1301-2, 1102-3	CCCGCTCGTCTTCCAGG	73	Antisense
16. 0101, 0102, 0403-08, 1402	CGGCCCGCCTCTGCTCC	74	Antisense
17. 1101, 1102, 1103, 1104	AGTCTCCTCATCAGGC	41	Antisense
18. 0302, 1402, DRB3*0301	GAAGTATCTCTCCAGGA	31	Antisense
19. 0301, 0302, 1301, 1302, 1402	CGCAGCTTCTCCTCTGGTTA	39	Antisense

adding 1:1 (vol/vol) phenol/chloroform to one volume of ESP extract. The mixture was centrifuged and DNA precipitated from the aqueous phase. Further purification of the genomic DNA was carried out using the Wizard DNA Clean-up System (Promega).

Genotyping was done using polymerase chain reaction (PCR), followed by sequence specific oligonucleotide (SSO) analysis⁵ (fig 1).

The PCR amplification of the genomic DNA was carried out using the following forward and reverse primers: 5'-TGTCATTTCTT CAATGGGACG and 5'-TCGCCGCTG CACTGTGAAG, respectively. The thermocycling parameters used for the amplification of genomic DNA were: denaturation for 30 seconds at 93°C, annealing for one minute at 55°C, and extension for two minutes at 72°C.

Approximately 0.5 µg of the PCR amplification product was subjected to electrophoresis in agarose gel (2%) and treated with denaturing solution followed by neutralising solution for one hour at room temperature. The blotting was performed overnight, DNA transferred to nylon filters (Hybond N) and probed with ³²P labelled oligonucleotide probes (table 1). The probes were labelled using [³²P] ATP (60 µCi), 10 pmol of oligonucleotide, and T4 polynucleotide kinase (NBL).

Following hybridisation, the membranes were washed twice at room temperature in 2× SSC (sodium chloride/sodium citrate) / 0.1% SDS, and then in 100 ml of tetramethyl ammonium chloride (TMAC) solution for 10 minutes; thereafter a final wash in TMAC was carried out at 56°C. For reprobing, the filters were strip washed by immersing the filter in 0.4 M NaOH at 42°C for 20 minutes followed by agitation in 0.2 M HCl (pH 8.0), 0.1 × SSPE (NaCl/NaH₂PO₄/EDTA) / 0.1% SDS for 20 minutes. The detection procedure was that recommended by The International Histocompatibility Workshop (Kimura and Suzuki, 1992).⁶ The oligonucleotide primers for PCR, SSO analysis were purchased from BSHI (the British Society for Histocompatibility and Immunogenetics, Bristol, UK).

Results

Two main DRB1 alleles observed in the patients were *080 and *070. Five of eight

Table 2 The frequency of HLA DRB1 alleles in the patients compared with normal white individuals

HLA DRB1 alleles	Allele frequency in	
	Patients	Controls†
*080	0.375	0.020
*070	0.313	0.133
*120	0.125	0.014
*140	0.125	0.028
*010	0.062	0.133

†The values for the distribution of HLA DRB1 alleles are compared with data given in references 4 and 5.

patients with giant cell tumours of bone were found to be positive for DRB1*0801/3 allele and four patients were positive for DRB1*070. In the patients, the gene frequency of *0801/3 was 0.380, which is 20-fold higher than the reported genotype frequency in British whites.^{4,5} Other DRB1 alleles observed in the patients were *120, *140, and *010. The frequency of DRB1 alleles in the patients is compared with that in the normal population in table 2.

Discussion

Although our study was performed on a comparatively small sample size, it shows a strong association with HLA-DRB1*080 alleles. All but one patient with HLA-DRB1*080 was found to have *070, suggesting that the 070/080 genotype may be associated with a particularly strong predisposition to HLA-DR negative giant cell tumour of bone. The other genotype observed in two patients was 120/140. The frequencies of *120 and *140 in the control population are known to be 0.014 and 0.028, respectively, while in the patients studied the frequency of these alleles was found to be 0.125 (table 2).

These data support a clear association between HLA-DRB1*080 and the formation of giant cell tumours of bone. The predominant haplotypes observed in our patients are those that have been identified in autoimmune disease but were not present in healthy controls.⁵ This observation raises a number of issues relating to the classification as well as the aetiology of giant cell tumour of bone. For instance, whether possessing the *080 allele increases the risk of giant cell tumour

formation in bone, or of multinucleate giant cell tumours in other tissues, needs to be established in a larger study. Further studies are needed to determine whether the observed association between giant cell tumour of bone and DRB1 is likely to occur in other giant cell lesions of bone and soft tissues.

The demonstration of a predominance of a particular HLA type II antigen in individuals at risk of developing giant cell tumour of bone is of interest in view of the recent developments in the area of osteoclast-like multinucleate cell formation. These recent studies have shown that the cytokines TRANCE/RANKL (tumour necrosis factor (TNF) related, activation induced cytokine), which is produced by osteoblasts and T lymphocytes, and M-CSF, which is produced by macrophages and other inflammatory cells, are essential for osteoclastogenesis.⁷⁻⁹ The mononuclear stromal cell component of giant cell tumour of bone is shown to contain largely osteoblast-like cells and macrophages.¹⁰ The signalling involved in stimulating the production of these cytokines from the stromal cells is not yet known, but the role of antigen presenting cells such as macrophages (APC cells) in this process is apparent from various previous studies demonstrating that the fusion of these cells requires monocyte/macrophage-bone stromal cell interaction.¹¹⁻¹³ Therefore surface molecules, such as HLA class II antigen, may be crucial in affecting the release of cytokines and the formation of osteoclasts and osteoclast-like giant cells in giant cell tumour of bone.

HKD thanks The Wishbone Trust for their support.

- 1 McGrath. Giant-cell tumour of bone: an analysis of fifty-two cases. *J Bone Joint Surg Br* 1972;**54**:216-29.
- 2 Doussis IA, Puddle B, Athanasou NA. Immunophenotype of multinucleated and mononuclear cells in giant cell lesions of bone and soft tissue. *J Clin Pathol* 1992;**45**:398-404.
- 3 Rathod H, Malcolm AJ, Gillespie JL, et al. Characterization of a subtype of primary osteoclastoma: extracellular calcium but not calcitonin inhibits aggressive HLA-DR-positive osteoclastoma possessing 'functional' calcitonin receptors. *J Pathol* 1994;**174**:293-9.
- 4 Doherty DG, Vaughan RW, Donaldson PT, et al. HLA DQA, DQB, and DRB genotyping by oligonucleotide analysis: distribution of alleles and haplotypes in British Caucasoids. *Hum Immunol* 1992;**34**:53-63.
- 5 Vaughan RW. PCR-SSO typing for HLA-DRB alleles. *Eur J Immunogenet* 1991;**18**:69-74.
- 6 Kimura A, Suzuki T. Reference protocol for the HLA/DNA typing technique. In: Dsuji SK, Aizawa M, Sasazuki T, eds. 11th International Histocompatibility Workshop, vol 1. Oxford: Oxford University Press, 1991:397-419.
- 7 Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. *Proc Natl Acad Sci USA* 1998;**95**:3597-602.
- 8 Rifas L, Holliday LS, Gluck SL, et al. Activated T cells induce osteoclastogenesis. *Bone* 1998 (programme and abstracts);**23**:S195.
- 9 Manabe N, Chikuda H, Nakamura, et al. Suppression of B-lymphopoiesis in the *Klotho* mouse exhibiting low turnover osteoporosis. *Bone* 1998 (programme and abstracts);**23**:s234.
- 10 Joyner CJ, Quinn J, Triffitt JT, et al. Phenotypic characterisation of mononuclear and multinucleated cells of giant cell tumour of bone. *Bone Miner* 1992;**16**:37-49.
- 11 Suda T, Takahasi N, Martin TJ. Modulation of osteoclast differentiation. *Endocr Rev* 1992;**13**:66-80.
- 12 Fujikawa Y, Quinn J, Sabokbar A, et al. The human mononuclear osteoclast precursor circulates in the monocyte fraction. *Endocrinology* 1996;**139**:4058-60.
- 13 Fujikawa Y, Sabokbar A, Neale S, et al. Human osteoclast formation and bone resorption by monocytes and synovial macrophages in rheumatoid arthritis. *Ann Rheum Dis* 1996;**55**:1-7.